NCT06394167View on ClinicalTrials.gov

A Phase 1 Dose Escalation Study of Intravenous VX-993 in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

May 9, 2024

Primary Completion Date

February 18, 2025

Study Completion Date

February 18, 2025

Conditions
Pain
Interventions
DRUG

VX-993

Solution for IV administration.

DRUG

Placebo

Solution for IV administration.

Trial Locations (1)

66219

ICON Lenexa, Lenexa

All Listed Sponsors
lead

Vertex Pharmaceuticals Incorporated

INDUSTRY

NCT06394167 - A Phase 1 Dose Escalation Study of Intravenous VX-993 in Healthy Adults | Biotech Hunter | Biotech Hunter